Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.

Kümler I, Balslev E, Stenvang J, Brünner N, Ejlertsen B, Jakobsen EH, Nielsen DL.

BMC Cancer. 2019 Jun 13;19(1):573. doi: 10.1186/s12885-019-5788-9.

2.

Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.

Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF.

Breast Cancer Res Treat. 2019 Jun;175(3):713-719. doi: 10.1007/s10549-019-05200-4. Epub 2019 Mar 14.

PMID:
30877405
3.

Breast cancer mortality in synchronous bilateral breast cancer patients.

Mejdahl MK, Wohlfahrt J, Holm M, Balslev E, Knoop AS, Tjønneland A, Melbye M, Kroman N.

Br J Cancer. 2019 Apr;120(7):761-767. doi: 10.1038/s41416-019-0403-z. Epub 2019 Feb 26.

PMID:
30804429
4.

PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.

Stovgaard ES, Dyhl-Polk A, Roslind A, Balslev E, Nielsen D.

Breast Cancer Res Treat. 2019 Apr;174(3):571-584. doi: 10.1007/s10549-019-05130-1. Epub 2019 Jan 10. Review.

PMID:
30627961
5.

Skin tape stripping: Which layers of the epidermis are removed?

Sølberg J, Ulrich NH, Krustrup D, Ahlström MG, Thyssen JP, Menné T, Bonefeld CM, Gadsbøll AØ, Balslev E, Johansen JD.

Contact Dermatitis. 2019 May;80(5):319-321. doi: 10.1111/cod.13199. Epub 2019 Jan 30. No abstract available.

PMID:
30552768
6.

Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.

Asleh K, Lyck Carstensen S, Tykjaer Jørgensen CL, Burugu S, Gao D, Won JR, Jensen MB, Balslev E, Laenkholm AV, Nielsen DL, Ejlertsen B, Nielsen TO.

Int J Cancer. 2019 May 15;144(10):2578-2586. doi: 10.1002/ijc.31969. Epub 2018 Dec 6.

PMID:
30411790
7.

Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study.

Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF.

Breast. 2018 Dec;42:128-132. doi: 10.1016/j.breast.2018.09.004. Epub 2018 Sep 18.

8.

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.

Buhl ASK, Christensen TD, Christensen IJ, Nelausen KM, Balslev E, Knoop AS, Brix EH, Svensson E, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Nielsen D, Jensen PB.

Breast Cancer Res Treat. 2018 Nov;172(2):391-400. doi: 10.1007/s10549-018-4918-4. Epub 2018 Aug 11.

9.

Evidence of No Association Between Human Papillomavirus and Breast Cancer.

Bønløkke S, Blaakær J, Steiniche T, Høgdall E, Jensen SG, Hammer A, Balslev E, Strube ML, Knakkergaard H, Lenz S.

Front Oncol. 2018 Jun 8;8:209. doi: 10.3389/fonc.2018.00209. eCollection 2018.

10.

Diagnostic challenges in clinical, radiological and histopathological tests regarding papillomatous lesions of the breast.

Rasmussen BB, Balslev E, Jarle Christensen I, Lanng C, Bak A, Galatius H, Møller Talman ML, Sharghi Someh N, Vejborg I, Okholm M.

Breast. 2018 Aug;40:177-180. doi: 10.1016/j.breast.2018.05.006. Epub 2018 May 22.

11.

A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).

Lindman H, Andersson M, Ahlgren J, Balslev E, Sverrisdottir A, Holmberg SB, Bengtsson NO, Jacobsen EH, Jensen AB, Hansen J, Tuxen MK, Malmberg L, Villman K, Anderson H, Ejlertsen B, Bergh J, Blomqvist C; Swedish Breast Cancer Group (SweBCG), the Danish Breast Cancer Group (DBCG) and the Scandinavian Breast Cancer Group (SBG).

Eur J Cancer. 2018 May;94:79-86. doi: 10.1016/j.ejca.2018.02.016. Epub 2018 Mar 20.

PMID:
29547834
12.

Is DBCG abreast of new developments?

Offersen BV, Ejlertsen B, Balslev E, Flyger H, Gerdes AM, Hansen MK, Hølmich LR, Jensen MB, Kristensen B, Laenkholm AV, Mouridsen HT, Nielsen MH, Overgaard J, Tuxen M, Vejborg I, Christiansen P.

Acta Oncol. 2018 Jan;57(1):1-2. doi: 10.1080/0284186X.2017.1408960. Epub 2018 Jan 3. No abstract available.

PMID:
29297250
13.

An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG).

Laenkholm AV, Grabau D, Møller Talman ML, Balslev E, Bak Jylling AM, Tabor TP, Johansen M, Brügmann A, Lelkaitis G, Di Caterino T, Mygind H, Poulsen T, Mertz H, Søndergaard G, Bruun Rasmussen B.

Acta Oncol. 2018 Jan;57(1):83-89. doi: 10.1080/0284186X.2017.1404127. Epub 2017 Dec 5.

PMID:
29202622
14.

Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.

Stovgaard ES, Nielsen D, Hogdall E, Balslev E.

Acta Oncol. 2018 Jan;57(1):74-82. doi: 10.1080/0284186X.2017.1400180. Epub 2017 Nov 23. Review.

PMID:
29168430
15.

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials.

Jensen MB, Nielsen TO, Knoop AS, Laenkholm AV, Balslev E, Ejlertsen B.

Acta Oncol. 2018 Jan;57(1):135-140. doi: 10.1080/0284186X.2017.1400181. Epub 2017 Nov 23.

PMID:
29168407
16.

The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.

Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF.

Eur J Cancer. 2017 Dec;87:1-9. doi: 10.1016/j.ejca.2017.09.037. Epub 2017 Oct 27.

PMID:
29096155
17.

Loss-of-function mutations in filaggrin gene and malignant melanoma: a case-control study.

Thyssen JP, Andersen YMF, Balslev E, Szecsi PB, Stender S, Kaae J, Linneberg A, Skov L.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):242-244. doi: 10.1111/jdv.14532. Epub 2017 Sep 12.

PMID:
28833578
18.

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT.

J Clin Oncol. 2017 Aug 10;35(23):2639-2646. doi: 10.1200/JCO.2017.72.3494. Epub 2017 Jun 29.

PMID:
28661759
19.

Filaggrin loss-of-function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross-sectional studies.

Andersen YMF, Egeberg A, Balslev E, Jørgensen CLT, Szecsi PB, Stender S, Kaae J, Linneberg A, Gislason G, Skov L, Elias PM, Thyssen JP.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1038-1043. doi: 10.1111/jdv.14172. Epub 2017 Mar 6.

PMID:
28213896
20.

Expression Patterns of Biomarkers in Primary Tumors and Corresponding Metastases in Breast Cancer.

Kümler I, Balslev E, Knop AS, Brünner N, Klausen TW, Jespersen SS, Nielsen SL, Nielsen DL.

Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):13-19. doi: 10.1097/PAI.0000000000000380.

PMID:
27753656
21.

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.

Nielsen TO, Jensen MB, Burugu S, Gao D, Jørgensen CL, Balslev E, Ejlertsen B.

Clin Cancer Res. 2017 Feb 15;23(4):946-953. doi: 10.1158/1078-0432.CCR-16-1278. Epub 2016 Sep 6.

22.

Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers.

Gondos A, Jansen L, Heil J, Schneeweiss A, Voogd AC, Frisell J, Fredriksson I, Johansson U, Tvedskov TF, Jensen MB, Balslev E, Hartmann-Johnsen OJ, Sant M, Baili P, Agresti R, van de Velde T, Broeks A, Nogaret JM, Bourgeois P, Moreau M, Mátrai Z, Sávolt Á, Nagy P, Kásler M, Schrotz-King P, Ulrich C, Brenner H.

Acta Oncol. 2016 Jun;55(6):712-9. doi: 10.3109/0284186X.2015.1136751. Epub 2016 Feb 15.

PMID:
26878397
23.

Risk of non-sentinel node metastases in patients with symptomatic cancers compared to screen-detected breast cancers.

Tvedskov TF, Jensen MB, Balslev E, Garne JP, Vejborg I, Christiansen P, Ejlertsen B, Kroman N.

Acta Oncol. 2016;55(4):455-9. doi: 10.3109/0284186X.2015.1094186. Epub 2015 Oct 9.

PMID:
26452696
24.

Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.

Tvedskov TF, Jensen MB, Ejlertsen B, Christiansen P, Balslev E, Kroman N.

Breast Cancer Res Treat. 2015 Oct;153(3):599-606. doi: 10.1007/s10549-015-3560-7. Epub 2015 Sep 4.

PMID:
26341752
25.
26.

Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.

Kümler I, Balslev E, Poulsen TS, Nielsen SL, Nygård SB, Rømer MU, Christensen IJ, Høgdall E, Moreira J, Nielsen DL, Brünner N, Stenvang J.

Int J Cancer. 2015 Oct 15;137(8):2000-6. doi: 10.1002/ijc.29556. Epub 2015 Apr 27.

27.

Reduced risk of axillary lymphatic spread in triple-negative breast cancer.

Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF.

Breast Cancer Res Treat. 2015 Jan;149(1):229-36. doi: 10.1007/s10549-014-3225-y. Epub 2014 Dec 9.

PMID:
25488719
28.

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.

Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, Holmstrøm K, Høgdall E.

Front Oncol. 2014 Aug 15;4:207. doi: 10.3389/fonc.2014.00207. eCollection 2014.

29.

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Rask L, Balslev E, Søkilde R, Høgdall E, Flyger H, Eriksen J, Litman T.

Cell Oncol (Dordr). 2014 Jun;37(3):215-27. doi: 10.1007/s13402-014-0176-6. Epub 2014 Jul 16.

PMID:
25027758
30.

Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies.

Holm M, Tjønneland A, Balslev E, Kroman N.

Breast Cancer Res Treat. 2014 Aug;146(3):461-75. doi: 10.1007/s10549-014-3045-0. Epub 2014 Jul 10. Review.

PMID:
25007962
31.

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.

Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL.

Acta Oncol. 2014 Oct;53(10):1440-5. doi: 10.3109/0284186X.2014.921727. Epub 2014 Jul 3. No abstract available.

PMID:
24991893
32.

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

Jørgensen CL, Bjerre C, Ejlertsen B, Bjerre KD, Balslev E, Bartels A, Brünner N, Nielsen DL.

BMC Cancer. 2014 May 22;14:360. doi: 10.1186/1471-2407-14-360.

33.

Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma.

Kaae J, Szecsi PB, Meldgaard M, Espersen ML, Stender S, Johansen JD, Bandier J, Thyssen JP, Menné T, Nielsen SL, Høgdall E, Balslev E, Skov L.

Br J Dermatol. 2014 Jun;170(6):1380-1. doi: 10.1111/bjd.12911. No abstract available.

PMID:
24641578
34.

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.

Poulsen TS, Espersen ML, Kofoed V, Dabetic T, Høgdall E, Balslev E.

Int J Breast Cancer. 2013;2013:368731. doi: 10.1155/2013/368731. Epub 2013 Dec 5.

35.

Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.

Munch-Petersen HD, Rasmussen BB, Balslev E.

APMIS. 2014 Sep;122(9):750-4. doi: 10.1111/apm.12213. Epub 2013 Dec 21.

PMID:
24372587
36.

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.

Jørgensen CL, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B.

Acta Oncol. 2014 Jun;53(6):776-87. doi: 10.3109/0284186X.2013.865076. Epub 2013 Dec 20.

PMID:
24359601
37.

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

Jørgensen CL, Ejlertsen B, Bjerre KD, Balslev E, Nielsen DL, Nielsen KV.

BMC Cancer. 2013 Nov 12;13:541. doi: 10.1186/1471-2407-13-541.

38.

Robust and validated models to predict high risk of non-sentinel node metastases in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node.

Tvedskov TF, Jensen MB, Balslev E, Kroman N.

Acta Oncol. 2014 Feb;53(2):209-15. doi: 10.3109/0284186X.2013.806993. Epub 2013 Jun 17.

PMID:
23772767
39.

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Munro AF, Bartels A, Balslev E, Twelves CJ, Cameron DA, Brünner N, Bartlett JM.

Breast Cancer Res. 2013 Apr 9;15(2):R31. doi: 10.1186/bcr3411.

40.

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.

Kümler I, Brünner N, Stenvang J, Balslev E, Nielsen DL.

Breast Cancer Res Treat. 2013 Apr;138(2):347-58. doi: 10.1007/s10549-013-2476-3. Epub 2013 Mar 20. Review.

PMID:
23512247
41.

Cytokeratin on frozen sections of sentinel node may spare breast cancer patients secondary axillary surgery.

Stovgaard ES, Tvedskov TF, Lænkholm AV, Balslev E.

Patholog Res Int. 2012;2012:802184. doi: 10.1155/2012/802184. Epub 2012 May 9.

42.

High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node.

Tvedskov TF, Jensen MB, Lisse IM, Ejlertsen B, Balslev E, Kroman N.

Int J Cancer. 2012 Nov 15;131(10):2367-75. doi: 10.1002/ijc.27499. Epub 2012 Mar 28.

43.

Rising incidence of Merkel cell carcinoma.

Lyhne D, Lock-Andersen J, Dahlstrøm K, Drzewiecki KT, Balslev E, Muhic A, Krarup-Hansen A.

J Plast Surg Hand Surg. 2011 Dec;45(6):274-80. doi: 10.3109/2000656X.2011.613233.

PMID:
22250719
44.

TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.

Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO.

Breast Cancer Res Treat. 2012 Feb;132(1):225-34. doi: 10.1007/s10549-011-1896-1. Epub 2011 Dec 9.

PMID:
22160637
45.

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.

Nielsen KV, Ejlertsen B, Møller S, Jensen MB, Balslev E, Müller S, Knoop A, Mouridsen HT.

Mol Oncol. 2012 Feb;6(1):88-97. doi: 10.1016/j.molonc.2011.11.006. Epub 2011 Nov 26.

46.

Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node.

Tvedskov TF, Bartels A, Jensen MB, Paaschburg B, Kroman N, Balslev E, Brünner N.

APMIS. 2011 Dec;119(12):844-52. doi: 10.1111/j.1600-0463.2011.02768.x. Epub 2011 Oct 18.

PMID:
22085360
47.

High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer.

Rask L, Balslev E, Jørgensen S, Eriksen J, Flyger H, Møller S, Høgdall E, Litman T, Nielsen BS.

APMIS. 2011 Oct;119(10):663-73. doi: 10.1111/j.1600-0463.2011.02782.x. Epub 2011 Jun 17.

PMID:
21917003
48.

Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer.

Tvedskov TF, Jensen MB, Kroman N, Balslev E.

Breast Cancer Res Treat. 2012 Jan;131(1):223-9. doi: 10.1007/s10549-011-1720-y. Epub 2011 Aug 18.

PMID:
21850395
49.

Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer.

Bernsdorf M, Balslev E, Lykkesfeldt AE, Kroman N, Harder E, von der Maase H, Jakobsen EH, Grabau D, Ejlertsen B.

Breast Cancer Res Treat. 2011 Jul;128(1):165-70. doi: 10.1007/s10549-011-1535-x. Epub 2011 Apr 23.

PMID:
21516302
50.

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.

Bernsdorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B.

Breast Cancer Res Treat. 2011 Apr;126(2):463-70. doi: 10.1007/s10549-011-1352-2. Epub 2011 Jan 15.

PMID:
21234672

Supplemental Content

Loading ...
Support Center